These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 6377102)

  • 21. Studies on the specific fibrinolytic effect of human extrinsic (tissue-type) plasminogen activator in human blood and in various animal species in vitro.
    Korninger C; Collen D
    Thromb Haemost; 1981 Aug; 46(2):561-5. PubMed ID: 6795744
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Plasminogen activator response after DDAVP: a clinico-pharmacological study.
    Mannucci PM; Rota L
    Thromb Res; 1980 Oct; 20(1):69-76. PubMed ID: 7193918
    [No Abstract]   [Full Text] [Related]  

  • 23. Thrombin activatable fibrinolysis inhibitor (TAFI) affects fibrinolysis in a plasminogen activator concentration-dependent manner. Study of seven plasminogen activators in an internal clot lysis model.
    Guimarães AH; Rijken DC
    Thromb Haemost; 2004 Mar; 91(3):473-9. PubMed ID: 14983222
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Solution of methodological problems in prorenin measurement and investigations of tissue renin-angiotensin systems in the female reproductive tract.
    Hagemann A
    Dan Med Bull; 1997 Nov; 44(5):486-98. PubMed ID: 9408735
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Molecular basis of fibrinolysis, as relevant for thrombolytic therapy.
    Collen D; Lijnen HR
    Thromb Haemost; 1995 Jul; 74(1):167-71. PubMed ID: 8578451
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Physiologic and pharmacologic enhancement of fibrinolysis.
    Prowse CV; Cash JD
    Semin Thromb Hemost; 1984 Jan; 10(1):51-60. PubMed ID: 6367048
    [No Abstract]   [Full Text] [Related]  

  • 27. Plasminogen activator inhibitor type-1 determines plasmin formation in patients with ischaemic heart disease.
    Pedersen OD; Gram J; Jespersen J
    Thromb Haemost; 1995 May; 73(5):835-40. PubMed ID: 7482412
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Alcohol-induced upregulation of plasminogen activators and fibrinolytic activity in cultured human endothelial cells.
    Aikens ML; Grenett HE; Benza RL; Tabengwa EM; Davis GC; Booyse FM
    Alcohol Clin Exp Res; 1998 Apr; 22(2):375-81. PubMed ID: 9581643
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Induction of uPA release in human peripheral blood lymphocytes by [deamino-Cysl,D-Arg8]-vasopressin (dDAVP).
    Yamaguchi Y; Yamada K; Suzuki T; Wu YP; Kita K; Takahashi S; Ichinose M; Suzuki N
    Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E970-6. PubMed ID: 15198931
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effects of DDAVP and venous occlusion on the release of tissue-type plasminogen activator and von Willebrand factor in patients with panhypopituitarism.
    Juhan-Vague I; Conte-Devolx B; Aillaud MF; Mendez C; Oliver C; Collen D
    Thromb Res; 1984 Mar; 33(6):653-9. PubMed ID: 6609451
    [No Abstract]   [Full Text] [Related]  

  • 31. Biological and thrombolytic properties of proenzyme and active forms of human urokinase--IV. Variability in fibrinolytic response of plasma of several mammalian species.
    Lijnen HR; De Wreede K; Demarsin E; Collen D
    Thromb Haemost; 1984 Aug; 52(1):31-3. PubMed ID: 6495261
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Purification of human plasma prorenin and molecular changes in its activation by proteolytic enzymes].
    Imamura Y
    Nihon Jinzo Gakkai Shi; 1985 Jan; 27(1):1-12. PubMed ID: 3892101
    [No Abstract]   [Full Text] [Related]  

  • 33. [Determination of the inactive renin (prorenin) content in the blood plasma by a cryoactivation method].
    Uchitel' IA
    Lab Delo; 1982; (5):301-3. PubMed ID: 6178890
    [No Abstract]   [Full Text] [Related]  

  • 34. A comparative study using immunological and biological assay of the haemostatic responses to DDAVP infusion venous occlusion and exercise in normal men.
    Prowse CV; Farrugia A; Boulton FE; Tucker J; Ludlam CA; McLaren M; Belch JJ; Prentice CR; Dawes J; MacGregor IR
    Thromb Haemost; 1984 Feb; 51(1):110-4. PubMed ID: 6426076
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The inability of propranolol and aspirin to inhibit the response of fibrinolytic activity and factor VIII-antigen to infusion of DDAVP.
    Brommer EJ; Derkx FH; Barrett-Bergshoeff MM; Schalekamp MA
    Thromb Haemost; 1984 Feb; 51(1):42-4. PubMed ID: 6426080
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Comparison of different methods of prorenin activation].
    Bagni B; Squerzanti R; de Paoli Vitali E; Saccani Jotti G; Cavallini R; Farinelli A
    Radiol Med; 1980 Nov; 66(11):865-6. PubMed ID: 7012952
    [No Abstract]   [Full Text] [Related]  

  • 37. A novel assay of plasma prorenin using a renin inhibitor.
    Derkx FH; de Bruin RJ; van Gool JM; Rosmalen FM; van Hoek MJ; Beerendonk CC; Schalekamp MA
    J Hypertens Suppl; 1993 Dec; 11(5):S240-1. PubMed ID: 8158364
    [No Abstract]   [Full Text] [Related]  

  • 38. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
    Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
    Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Potential functions of plasma prorenin; regional activation and tissue extraction.
    Thatcher RL; Butty JS; Whitworth JA; Hunt VD; Shaw PF; Skinner SL; Horowitz JD
    Clin Exp Hypertens A; 1987; 9(8-9):1415-34. PubMed ID: 3308199
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Staphylokinase reduces plasmin formation by endogenous plasminogen activators.
    Jin T; Bokarewa M; Zhu Y; Tarkowski A
    Eur J Haematol; 2008 Jul; 81(1):8-17. PubMed ID: 18331597
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.